<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442403</url>
  </required_header>
  <id_info>
    <org_study_id>FSP 97008500</org_study_id>
    <nct_id>NCT00442403</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Chloroquine Associated With Dehydroepiandrosterone Sulphate to Treat Uncomplicated Falciparum Malaria</brief_title>
  <official_title>Etude de l’Activite (Efficacite et Tolerance) de l’Association de la Chloroquine Avec la Dehydroepiandrosterone-Sulfate (Dheas) Dans le Traitement de l’Acces Palustre Simple A Plasmodium Falciparum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Victor Segalen Bordeaux 2</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Victor Segalen Bordeaux 2</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and efficacy of a standard chloroquine drug regimen
      administration supplemented with dehydroepiandrosterone sulfate against drug-resistant
      malaria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Worldwide progression of Plasmodium falciparum chloroquine (CQ), amodiaquine and
      sulfadoxine-pyrimethamine resistance leaves few alternative for the control of malaria,
      particularly in Africa. For some strains of P. falciparum and P. berghei, the resistance to
      CQ and AQ is linked to an increase in reduced glutathione (GSH) levels and GSH-related enzyme
      activity, such as glucose 6-phosphate deshydrogenase (G6PD). The pro-hormone
      dehydroepiandrosterone sulphate can be used to potentiate the antimalarial action of CQ on
      drug resistant P. falciparum strains, by inhibiting parasite G6PD activity. This hormone has
      a second advantage: it is metabolised in human into a series of potent immunomodulatory
      steroids which may be in the causal pathway that allowed the induction of protective immune
      responses against several infections, included malaria. This first study evaluated the
      tolerance and efficacy of a standard CQ regimen supplemented with dehydroepiandrosterone
      sulphate for the treatment of drug resistant uncomplicated falciparum malaria.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line
    therapy for of uncomplicated malaria.
  </why_stopped>
  <start_date>April 2002</start_date>
  <completion_date>September 2002</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of any adverse event;</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of clinical and/or parasitological failure during the 14 days of follow up.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with positive blood smear during follow-u;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean parasitemia during follow-up;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical symptoms on day 3.</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Malaria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chloroquine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dehydroepiandrosterone sulphate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signing an informed consent (informed consent was given by legal guardian for
             children);

          -  age egal or more than 15 years;

          -  fever (axillary temperature egal or more than 37.5 °C and less than 40°C) or a history
             of fever within the last 24 hours;

          -  no sign suggestive of other febrile illness;

          -  absence of signs of complicated malaria (WHO criteria);

          -  willingness to participate in follow-up for 14 days

          -  a positive thick blood film for P. falciparum without other detectable infectious
             microorganisms

        Exclusion Criteria:

          -  patients taking glucocorticoids or other immuno-suppressive drugs, or indicating
             recent antimalarial drug history (verbal questionnaire);

          -  severe malaria;

          -  mixed infections;

          -  women using contraceptives;

          -  pregnant women;

          -  breast-feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel LE BRAS, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Université Victor Segalen Bordeaux 2, Centre René Labusquière (Santé et Développement)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal MILLET, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Victor Segalen Bordeaux 2, Pôle des Maladies Tropicale, CHU de Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Medical Research and study of Medicinal Plants, Medical Research Center</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <reference>
    <citation>Libonati RM, de Mendonça BB, Maués JA, Quaresma JA, de Souza JM. Some aspects of the behavior of the hypothalamus-pituitary-adrenal axis in patients with uncomplicated Plasmodium falciparum malaria: Cortisol and dehydroepiandrosterone levels. Acta Trop. 2006 Jul;98(3):270-6. Epub 2006 Jul 17.</citation>
    <PMID>16846568</PMID>
  </reference>
  <reference>
    <citation>Libonati RM, Cunha MG, Souza JM, Santos MV, Oliveira SG, Daniel-Ribeiro CT, Carvalho LJ, do Nascimento JL. Estradiol, but not dehydroepiandrosterone, decreases parasitemia and increases the incidence of cerebral malaria and the mortality in plasmodium berghei ANKA-infected CBA mice. Neuroimmunomodulation. 2006;13(1):28-35. Epub 2006 May 12.</citation>
    <PMID>16699290</PMID>
  </reference>
  <reference>
    <citation>Safeukui I, Mangou F, Malvy D, Vincendeau P, Mossalayi D, Haumont G, Vatan R, Olliaro P, Millet P. Plasmodium berghei: dehydroepiandrosterone sulfate reverses chloroquino-resistance in experimental malaria infection; correlation with glucose 6-phosphate dehydrogenase and glutathione synthesis pathway. Biochem Pharmacol. 2004 Nov 15;68(10):1903-10.</citation>
    <PMID>15476661</PMID>
  </reference>
  <reference>
    <citation>Leenstra T, ter Kuile FO, Kariuki SK, Nixon CP, Oloo AJ, Kager PA, Kurtis JD. Dehydroepiandrosterone sulfate levels associated with decreased malaria parasite density and increased hemoglobin concentration in pubertal girls from western Kenya. J Infect Dis. 2003 Jul 15;188(2):297-304. Epub 2003 Jul 1.</citation>
    <PMID>12854087</PMID>
  </reference>
  <reference>
    <citation>Ayi K, Giribaldi G, Skorokhod A, Schwarzer E, Prendergast PT, Arese P. 16alpha-bromoepiandrosterone, an antimalarial analogue of the hormone dehydroepiandrosterone, enhances phagocytosis of ring stage parasitized erythrocytes: a novel mechanism for antimalarial activity. Antimicrob Agents Chemother. 2002 Oct;46(10):3180-4.</citation>
    <PMID>12234842</PMID>
  </reference>
  <reference>
    <citation>Kurtis JD, Mtalib R, Onyango FK, Duffy PE. Human resistance to Plasmodium falciparum increases during puberty and is predicted by dehydroepiandrosterone sulfate levels. Infect Immun. 2001 Jan;69(1):123-8.</citation>
    <PMID>11119497</PMID>
  </reference>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <last_update_submitted>February 28, 2007</last_update_submitted>
  <last_update_submitted_qc>February 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2007</last_update_posted>
  <keyword>Malaria</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Chloroquine</keyword>
  <keyword>Dehydroepiandrosterone sulphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

